Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H15ClN2O4S2 |
| Molecular Weight | 434.916 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCCC1=CC2=CC(Cl)=CC=C2N1S(=O)(=O)C3=CC4=C(C=C3)N=CS4
InChI
InChIKey=OQDQIFQRNZIEEJ-UHFFFAOYSA-N
InChI=1S/C19H15ClN2O4S2/c20-13-4-7-17-12(8-13)9-14(2-1-3-19(23)24)22(17)28(25,26)15-5-6-16-18(10-15)27-11-21-16/h4-11H,1-3H2,(H,23,24)
| Molecular Formula | C19H15ClN2O4S2 |
| Molecular Weight | 434.916 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:04:13 UTC 2023
by
admin
on
Sat Dec 16 12:04:13 UTC 2023
|
| Record UNII |
28Q8AG0PYL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
470315
Created by
admin on Sat Dec 16 12:04:13 UTC 2023 , Edited by admin on Sat Dec 16 12:04:13 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/14/1361
Created by
admin on Sat Dec 16 12:04:13 UTC 2023 , Edited by admin on Sat Dec 16 12:04:13 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB14801
Created by
admin on Sat Dec 16 12:04:13 UTC 2023 , Edited by admin on Sat Dec 16 12:04:13 UTC 2023
|
PRIMARY | |||
|
28Q8AG0PYL
Created by
admin on Sat Dec 16 12:04:13 UTC 2023 , Edited by admin on Sat Dec 16 12:04:13 UTC 2023
|
PRIMARY | |||
|
SUB184623
Created by
admin on Sat Dec 16 12:04:13 UTC 2023 , Edited by admin on Sat Dec 16 12:04:13 UTC 2023
|
PRIMARY | |||
|
EU/3/14/1362(POSITIVE)
Created by
admin on Sat Dec 16 12:04:13 UTC 2023 , Edited by admin on Sat Dec 16 12:04:13 UTC 2023
|
PRIMARY | On 19 November 2014, orphan designation (EU/3/14/1362) was granted by the European Commission to Inventiva, France, for 1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid for the treatment of idiopathic pulmonary fibrosis. | ||
|
C166556
Created by
admin on Sat Dec 16 12:04:13 UTC 2023 , Edited by admin on Sat Dec 16 12:04:13 UTC 2023
|
PRIMARY | |||
|
10474
Created by
admin on Sat Dec 16 12:04:13 UTC 2023 , Edited by admin on Sat Dec 16 12:04:13 UTC 2023
|
PRIMARY | |||
|
68677842
Created by
admin on Sat Dec 16 12:04:13 UTC 2023 , Edited by admin on Sat Dec 16 12:04:13 UTC 2023
|
PRIMARY | |||
|
927961-18-0
Created by
admin on Sat Dec 16 12:04:13 UTC 2023 , Edited by admin on Sat Dec 16 12:04:13 UTC 2023
|
PRIMARY | |||
|
100000170566
Created by
admin on Sat Dec 16 12:04:13 UTC 2023 , Edited by admin on Sat Dec 16 12:04:13 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST |
AGONIST
EC50
|
||
|
TARGET -> AGONIST |
AGONIST
EC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
RESULTS: In mice, IVA337 was associated with decreased extracellular matrix (ECM) deposition and reduced expression of phosphorylated SMAD2/3-intracellular effector of transforming growth factor (TGF)-.BETA.1. Although the antifibrotic effect of pan PPAR was similar to that of PPAR.GAMMA. agonist alone, a significant downregulation of several markers of inflammation was associated with IVA337. Despite its anti-inflammatory and antifibrotic properties, IVA337 did not interfere with wound closure. In vitro effects of IVA337 included attenuation of transcription of ECM genes and alteration of canonical and non-canonical TGF-.BETA. signalling pathways.
CONCLUSIONS: These findings indicate that simultaneous activation of all three PPAR isoforms exerts a dampening effect on inflammation and fibrosis, making IVA337 a potentially effective therapeutic candidate in the treatment of fibrotic diseases including SSc.
|
